Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 1,360 | 0.91 |
| pathways Reactome | 8 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5683
Sealed predictions
- KMT2D in dopamine neurons, braak-0.45 (p 0.225) → -0.21 (p 0.581)receipt 5691
Swarm cases
receipt 5691: KMT2D in dopamine neurons, braak
- power
- full sample -0.44 (p 0.070, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.46 (p 0.052, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.016, n 18). not the mix.
- skeptic
- leave-one-out range -0.56 to -0.37, sign flips 0; without severely affected donors -0.44 (p 0.070, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KMT2D in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts